Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Novartis AGNYSE: NVS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income declines year over year
Q2 FY2026 net income of $3.27B fell 18.8% year over year, behind the -6.4% change in trailing-twelve-month net income. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at +32.5% a year.
Context
- Net income amounted to 25.6% of revenue in FY2025, up 2.6 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 12 analysts of $17.42B (+24.0%) for the fiscal year ending Dec 2026, a step up from the +17.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.27B+3.5% QoQ
- Last fiscal yearDec 2025
- $14.06B+17.7% YoY
- LTMJun 2026
- $12.76B-6.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -18.8% | +10.1% | +28.9 pp |
| 1 year | +17.7% | +24.0% | +6.2 pp |
| 3-year CAGR | +32.5% | +14.6% | -17.8 pp |
| 5-year CAGR | +12.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 14.06B USD
- Year-over-year change
- +17.7%
- 4-year CAGR
- -11.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.06B | +17.7% |
| FY2024 | 2024-12-31 | 11.94B | +39.3% |
| FY2023 | 2023-12-31 | 8.57B | +41.7% |
| FY2022 | 2022-12-31 | 6.05B | -73.6% |
| FY2021 | 2021-12-31 | 22.91B | — |
Net Income vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.4% is the 6th highest of 11, against a peer median of -6.1%.
- Net income amounts to 22.9% of revenue for NVS, versus a peer median of 16.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 116.44B DKK | +4.8% | +22.6% | 35.3% | |
| LTM Sep 2026 | $16.1B USD | -35.9% | +14.3% | 16.2% | |
| LTM Jun 2026 | $12.76B USD | -6.4% | +32.5% | 22.9% | |
| LTM Sep 2026 | $11.82B USD | +15.4% | +59.9% | 19.0% | |
| LTM Jun 2026 | $9.27B USD | +83.1% | +3.6% | 18.9% | |
| LTM Jun 2026 | $6.32B USD | +66.4% | -29.1% | 9.8% | |
| LTM Jun 2026 | £5.62B GBP | +41.0% | +0.6% | 16.9% | |
| LTM Jun 2026 | $5.24B USD | -17.0% | +22.8% | 17.2% | |
| LTM Jun 2026 | $4.37B USD | -59.4% | -37.2% | 6.9% | |
| LTM Jun 2026 | €3.96B EUR | -46.8% | -11.2% | 8.1% | |
| LTM Jun 2026 | $3.17B USD | -80.7% | +7.9% | 4.8% | |
| Peer median (excluding NVS) | — | -6.1% | +5.8% | 16.6% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.91B | 6.05B | 8.57B | 11.94B | 14.06B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| Deferred Income Tax | 1.63B | 1.13B | 551M | 1.7B | (361.84M) |
| Stock-Based Compensation | 700M | 791M | 865M | 1.04B | 0 |
| Change in Working Capital | (73M) | (796M) | (369M) | (706M) | (3.08B) |
| Accounts Receivables | (352M) | (397M) | (1.5B) | (931M) | (1.13B) |
| Inventory | (102M) | (560M) | (546M) | (225M) | 34.17M |
| Accounts Payables | (111M) | (181M) | 479M | (105M) | (274.4M) |
| Other Working Capital | 492M | 342M | 1.2B | 555M | (1.71B) |
| Other Non-Cash Items | (15.68B) | 359M | (3.44B) | (2.43B) | 3.27B |
| Operating Cash Flow | 15.07B | 14.24B | 14.46B | 17.62B | 19.24B |
| Capital Expenditures | (2.56B) | (2.24B) | (2.75B) | (3.81B) | (1.56B) |
| Acquisitions (Net) | 20.46B | (864M) | (3.57B) | (3.83B) | (3.01B) |
| Purchases of Investments | (16.59B) | (34.81B) | (747M) | (3.65B) | (304.55M) |
| Sales of Investments | 2.74B | 39.49B | 11.6B | 3.7B | 2.19B |
| Other Investing Activities | (1.34B) | (1.43B) | (624M) | (2.38B) | 140.72M |
| Investing Cash Flow | 4.21B | 1.47B | 5.6B | (7.51B) | (4.9B) |
| Debt Repayment | (5.67B) | (2.59B) | (1.94B) | 4.39B | 2.72B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 27.14M |
| Common Stock Repurchased | (3.06B) | (10.65B) | (8.72B) | (8.33B) | (9.26B) |
| Dividends Paid | (7.37B) | (7.51B) | (7.26B) | (7.62B) | (7.86B) |
| Other Financing Activities | (169M) | 181M | 3.63B | (177M) | (577.95M) |
| Financing Cash Flow | (16.26B) | (20.56B) | (14.28B) | (11.74B) | (14.94B) |
| Effect of Forex Changes | (266M) | (32M) | 100M | (298M) | 579.07M |
| Net Change in Cash | 2.75B | (4.89B) | 5.88B | (1.93B) | (24M) |
| Free Cash Flow | 12.52B | 12B | 11.71B | 13.81B | 17.69B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.